A Phase 1 Study Of Cmc-544 Administered As A Single Agent In Subjects With B-cell Non- Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- 02 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 02 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Dec 2010 Additional trial locations identified as reported by ClinicalTrials.gov.